Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

JAMA Oncology

Topics

Medicine

Cancer Oncology

Pathology

Internal Medicine

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1001/jamaoncol.2018.3039